O'Rourke Diana, Coll-Padrós Nina, Bradshaw Angela, Killin Lewis, Pradier Laurent, Georges Jean, Dawoud Dalia M, Steukers Lennert, Diaz Carlos
National Institute for Health and Care Excellence, Manchester, United Kingdom.
SYNAPSE Research Management Partners, Barcelona, Spain.
Front Neurol. 2022 Nov 2;13:994301. doi: 10.3389/fneur.2022.994301. eCollection 2022.
The IMI public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) was launched in 2008 with an initial budget of €2 billion. Aiming to accelerate the development of innovative medicines for areas of unmet clinical need, the IMI has committed over €380 million to projects on neurodegenerative disorders (NDD), catalyzing public-private collaborations at scale and at all stages of the R&D pipeline. Because of this vast investment, research on neurodegenerative diseases has made enormous strides in recent decades. The challenge for the future however remains to utilize this newly found knowledge and generated assets to develop better tools and novel therapeutic strategies. Here, we report the results of an integrated programme analysis of the IMI NDD portfolio, performed by the Neuronet Coordination and Support Action. Neuronet was launched by the IMI in 2019 to boost synergies and collaboration between projects in the IMI NDD portfolio, to increase the impact and visibility of research, and to facilitate interactions with related initiatives worldwide. Our analysis assessed the characteristics, structure and assets of the project portfolio and identifies lessons from projects spanning preclinical research to applied clinical studies and beyond. Evaluation of project parameters and network analyses of project partners revealed a complex web of 236 partnering organizations, with EFPIA partners often acting as connecting nodes across projects, and with a great diversity of academic institutions. Organizations in the UK, Germany, France and the Netherlands were highly represented in the portfolio, which has a strong focus on clinical research in Alzheimer's and Parkinson's disease in particular. Based on surveys and unstructured interviews with NDD research leaders, we identified actions to enhance collaboration between project partners, by improving the structure and definition of in-kind contributions; reducing administrative burdens; and enhancing the exploitation of outcomes from research investments by EU taxpayers and EFPIA. These recommendations could help increase the efficiency and impact of future public-private partnerships on neurodegeneration.
欧盟委员会与欧洲制药工业协会联合会（EFPIA）之间的创新药物倡议（IMI）公私合作伙伴关系于2008年启动，初始预算为20亿欧元。IMI旨在加速针对未满足临床需求领域的创新药物开发，已为神经退行性疾病（NDD）项目投入超过3.8亿欧元，推动了大规模的公私合作以及研发管道各阶段的合作。由于这笔巨额投资，近几十年来神经退行性疾病的研究取得了巨大进展。然而，未来的挑战仍然是利用这些新发现的知识和产生的资产来开发更好的工具和新颖的治疗策略。在此，我们报告了由Neuronet协调与支持行动对IMI NDD项目组合进行的综合项目分析结果。Neuronet由IMI于2019年发起，旨在促进IMI NDD项目组合中各项目之间的协同作用与合作，提高研究的影响力和知名度，并促进与全球相关倡议的互动。我们的分析评估了项目组合的特征、结构和资产，并从临床前研究到应用临床研究及其他领域的项目中总结经验教训。对项目参数的评估和对项目合作伙伴的网络分析揭示了一个由236个合作组织构成的复杂网络，EFPIA的合作伙伴常常充当跨项目的连接节点，且学术机构种类繁多。英国、德国、法国和荷兰的组织在该项目组合中占比很高，该项目组合尤其侧重于阿尔茨海默病和帕金森病的临床研究。基于对NDD研究领导者的调查和非结构化访谈，我们确定了通过改善实物贡献的结构和定义、减轻行政负担以及加强对欧盟纳税人及EFPIA研究投资成果的利用来加强项目合作伙伴之间合作的行动。这些建议有助于提高未来公私合作在神经退行性疾病研究方面的效率和影响力。
